Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke

Inclusion Criteria: * Acute ischemic stroke; * 18 to 80 years of age; * There are clear signs of neurological deficit: 8≤NIHSS score≤24; * Received alteplase thrombolysis therapy within 4.5 hours after onset; * Patients signed written inform consent Exclusion Criteria: * Patients need endovascular therapy or bridge therapy; * Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage; * Severe head trauma or stroke, intracranial tumor or large intracranial aneurysm within 3 months; * Intracranial or intraspinal surgery within 3 months; * Active visceral hemorrhage * Major surgery within 2 weeks or arterial puncture within 1 week that is difficult to compress the hemostatic site; * Unknown onset time; * Rapid improvement of symptoms or mild symptoms before thrombolysis therapy; * A platelet count below 100,000/mm3 indicates a propensity for acute bleeding; * Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase; * Patients with severe mental disorders and dementia; * ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis; * Serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less than 50 ml/min or previously known severe renal diseases; * Patients with malignant tumors or severe systemic disease; * allergic to edaravone , (+)-Borneol or related excipients; * Pregnant or lactating women; * Have major surgery within 4 weeks before enrollment; * Participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present; * The investigators consider the patients are not suitable for this trial.